Want to see JP:4538 full AI Analyst Report?
Top Page
Fuso Pharmaceutical Industries,Ltd.
(4538)
Select Model
Select Model
Rating:64Neutral
Price Target:
¥2,433.00
▲(5.10% Upside)
Action:Reiterated
Date:08/17/26
The score is held back mainly by weakened financial performance—especially negative operating/free cash flow and higher leverage—despite strong revenue growth. Offsetting this, technicals show positive momentum and valuation is supportive with a low P/E and a near-4% dividend yield.
Positive Factors
Strong Revenue Growth
A sustained upward revenue trend indicates expanding demand for Fuso’s prescription medicines. The FY2026 acceleration provides a stronger top-line base, which can support operating leverage if production efficiency and pricing remain controlled.
Negative Factors
Rising Leverage
The faster increase in debt than equity has reduced balance-sheet flexibility. Higher leverage can constrain investment capacity and increase vulnerability if profitability weakens, making future earnings recovery more important to financial stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
A sustained upward revenue trend indicates expanding demand for Fuso’s prescription medicines. The FY2026 acceleration provides a stronger top-line base, which can support operating leverage if production efficiency and pricing remain controlled.
Read all positive factors
Fuso Pharmaceutical Industries,Ltd. (4538) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥20.26B
Dividend Yield3.9%
Average Volume (3M)17.49K
Price to Earnings (P/E)9.0
Beta (1Y)0.53
Revenue Growth2.29%
EPS GrowthN/A
CountryJP
Employees1,370
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)256.65
Shares Outstanding9,451,169
10 Day Avg. Volume18,340
30 Day Avg. Volume17,486
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.58
Price to Sales (P/S)0.32
P/FCF Ratio-2.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fuso Pharmaceutical Industries,Ltd. Business Overview & Revenue Model
Company Description
Fuso Pharmaceutical Industries, Ltd. is a Japanese firm primarily involved in the development and commercialization of pharmaceutical goods. Their product range encompasses prescription medications, particularly injectables and solutions for artif...
How the Company Makes Money
Fuso Pharmaceutical Industries makes money primarily by selling prescription pharmaceutical products in Japan. Its revenue model is centered on (1) product sales of medical-use drugs—especially hospital-oriented formulations such as injectables—su...
Fuso Pharmaceutical Industries,Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
58
Neutral
Cash Flow
29
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.85B | 62.31B | 60.56B | 55.41B | 51.02B | 49.63B |
| Gross Profit | 16.11B | 15.99B | 16.19B | 13.52B | 13.36B | 12.91B |
| EBITDA | 5.65B | 5.38B | -2.98B | 3.67B | 4.63B | 4.47B |
| Net Income | 2.19B | 2.01B | -3.29B | 1.38B | 1.60B | 1.48B |
Balance Sheet | ||||||
| Total Assets | 87.47B | 90.32B | 82.52B | 76.46B | 72.81B | 69.66B |
| Cash, Cash Equivalents and Short-Term Investments | 4.57B | 4.85B | 6.26B | 5.12B | 8.01B | 7.35B |
| Total Debt | 26.31B | 28.46B | 21.29B | 12.72B | 11.41B | 12.09B |
| Total Liabilities | 51.72B | 55.26B | 49.48B | 39.79B | 37.15B | 35.12B |
| Stockholders Equity | 35.75B | 35.06B | 33.04B | 36.66B | 35.65B | 34.53B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -7.49B | -5.43B | -2.62B | 1.32B | 2.20B |
| Operating Cash Flow | 0.00 | -6.22B | -3.31B | 627.00M | 2.87B | 3.61B |
| Investing Cash Flow | 0.00 | -1.51B | -3.17B | -3.54B | -1.39B | -1.66B |
| Financing Cash Flow | 0.00 | 6.32B | 7.62B | 14.00M | -813.00M | -1.67B |
Fuso Pharmaceutical Industries,Ltd. Technical Analysis
Positive
2315.00
Price Trends
2179.26
Positive
2167.69
Positive
2218.82
Positive
Market Momentum
39.07
Negative
63.47
Neutral
61.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4538, the sentiment is Positive. The current price of 2315 is above the 20-day moving average (MA) of 2240.10, above the 50-day MA of 2179.26, and above the 200-day MA of 2218.82, indicating a bullish trend. The MACD of 39.07 indicates Negative momentum. The RSI at 63.47 is Neutral, neither overbought nor oversold. The STOCH value of 61.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4538.
Fuso Pharmaceutical Industries,Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥9.14B | 11.66 | ― | 2.55% | 0.98% | 69.36% | |
64 Neutral | ¥20.26B | 9.00 | ― | 3.71% | 2.29% | ― | |
54 Neutral | ¥5.68B | -45.84 | ― | 3.21% | 0.60% | -131.22% | |
53 Neutral | ¥13.42B | 19.28 | ― | ― | 13.30% | 66.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥10.79B | 31.24 | ― | 1.06% | 25.89% | ― | |
42 Neutral | ¥18.05B | 41.98 | ― | 4.37% | 8.42% | 49.52% |
* Healthcare Sector Average
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,309.00
236.46
11.41%
JP:2929
Pharma Foods International Co., Ltd.
618.00
-303.35
-32.92%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
308.00
2.57
0.84%
JP:4524
Morishita Jintan Co., Ltd.
2,244.00
95.63
4.45%
JP:4539
Nippon Chemiphar Co., Ltd.
1,574.00
9.67
0.62%
JP:4574
Taiko Pharmaceutical Co., Ltd.
264.00
-41.00
-13.44%
Fuso Pharmaceutical Industries,Ltd. Corporate Events
Fuso Pharmaceutical Delivers Strong Q1 Profit Jump but Keeps Cautious Full-Year Outlook
Aug 10, 2026
Fuso Pharmaceutical Industries reported solid first-quarter non-consolidated results for the three months ended June 30, 2026, with net sales up 3.5% year-on-year to ¥16,046 million and operating profit surging 63.0% to ¥972 million, lif...
Fuso Pharmaceutical Profit Falls Despite Higher Sales as Dividend Rises
May 18, 2026
Fuso Pharmaceutical reported a 2.9% rise in net sales to ¥62.3 billion for the year ended March 31, 2026, but saw operating profit drop 36.1% to ¥2.64 billion and ordinary profit fall 37.9% to ¥2.35 billion, even as it swung from a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.